SRR4195655
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.450
- PROTEIN_SECRETION+0.410
- E2F_TARGETS+0.350
- G2M_CHECKPOINT+0.350
- ALLOGRAFT_REJECTION+0.300
- MTORC1_SIGNALING+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.260
- SPERMATOGENESIS+0.240
- MYC_TARGETS_V1+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.470
- MYOGENESIS-0.390
- HEDGEHOG_SIGNALING-0.350
- COAGULATION-0.330
- WNT_BETA_CATENIN_SIGNALING-0.320
- BILE_ACID_METABOLISM-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- NOTCH_SIGNALING-0.290
- TNFA_SIGNALING_VIA_NFKB-0.270
- XENOBIOTIC_METABOLISM-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0122212 | — | — | 0.894 |
| 2 | SRR2016949 | — | — | 0.886 |
| 3 | SRR4195675 | — | — | 0.863 |
| 4 | SRR12475138 | — | — | 0.861 |
| 5 | SRR8518162 | — | E | 0.841 |
| 6 | TCGA-55-A4DF-01A-11R-A24H-07 | — | cohortA3 | 0.825 |
| 7 | SRR12202438 | — | — | 0.807 |
| 8 | C3L-02654 | — | cohortA1 | 0.802 |
| 9 | GSM6454730 | — | D | 0.801 |
| 10 | SRR8518291 | — | D | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |